Genomic Vision Expands Its Replication Combing Assay Service Offering
November 02 2023 - 2:00AM
Business Wire
- Genomic Vision expands its Replication Combing Assay (RCA)
services to meet specific pharmaceutical needs, resulting in
invaluable insights.
- Genomic Vision now can provide new replication parameters
that allow a better understanding of the mechanism of action of
drugs and help define the role of some pathways in cancer
progression.
- Total sales linked to the RCA service have risen by over 60%
between 2022 and 2023.
Regulatory News:
Genomic Vision (FR0011799907 – GV, the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of transformed
cells is pleased to announce the expansion of its RCA services,
emphasising its ongoing commitment to developing its services
offers for oncology and drug discovery.
Going beyond the standard RCA offerings and bringing tailored
solutions, Genomic Vision now can provide new replication
parameters like fork speed, analog ratio, fork symmetry, fork
stalling and new origin firing.
Genomic Vision also offers a new Locus-RCA service, which is
attracting growing interest in the scientific community, allowing
the assessment of replication dynamic changes in a specific region
of the genome, like oncogenes and tumor suppressor genes.
Genomic Vision is proud to deliver tailored RCA services to meet
specific needs, demonstrating its commitment to providing
customised genomic solutions to its partners, ultimately driving
advancements in the pharmaceutical and biotechnology
industries.
Total sales linked to the RCA service have risen by over 60% in
a year. Indeed, between 2022 and 2023, GV achieved an
outperformance in the pharmaceutical industry segment, while also
seeing constant positive growth in the number of requests from
academic laboratories.
Additionally, Genomic Vision's Research & Development team
is actively conducting experiments to offer an even more expanded
range of parameters and biomarkers for analysis within the RCA
framework, further enhancing the capabilities and insights
available to its clients.
Aurélien Petit, Services & Support Director at Genomic
Vision, expressed his satisfaction, saying, “Having recently
announced a reduction in the turnaround time for our RCA service,
we are proud to be able to offer our customers new RCA parameters,
while maintaining our fast and efficient service delivery. This
enhancement not only underlines our commitment to meeting the
ever-changing demands of this dynamic industry, but also responds
to growing enquiries, reaffirming our ability to deliver
cutting-edge solutions quickly.”
ABOUT GENOMIC VISION GENOMIC VISION is a biotechnology
company that develops products and services for the highly accurate
characterization of genome modifications. We deliver high-quality
integrated genomic analysis solutions to improve quality control
and bioproduction standards of advanced gene therapies at scale.
Based on molecular combing technology and artificial intelligence,
The Company provides robust quantitative measurements needed for
high confidence characterization of transformed cell lines and
prediction of cell line performance, in particular in the context
of the biomanufacturing processes of cell and gene therapies.
Genomic Vision’s molecular combing technology has further
applications in drug development of agents targeting DNA
replication and damage response mechanisms, visualizing DNA
replication kinetics and telomere length maintenance. Genomic
Vision, based near Paris in Bagneux, is a public company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
– ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC® Mid & Small and CAC® All-Tradable
indices
FORWARD LOOKING STATEMENT This press release contains
implicitly or explicitly certain forward-looking statements
concerning Genomic Vision and its business. Such forward-looking
statements are based on assumptions that Genomic Vision considers
to be reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
“Risk Factors” section of the universal registration document filed
with the AMF on April 28, 2023 under number D.23-0383, available on
the web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with its Financing
partner.
The shares resulting from the conversion or exercise of the
aforementioned securities will, in general, be sold on the market,
which could create downward pressure on the share price as well as
a dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101724730/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board +33 1 49 08 07 51 investisseurs@genomicvision.com
NewCap France Investor Relations & Strategic
Communications +33 1 44 71 94 94 gv@newcap.eu
Visionary (NASDAQ:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Visionary (NASDAQ:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024